Matches in SemOpenAlex for { <https://semopenalex.org/work/W2596095025> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2596095025 abstract "e15510 Background: The combination of fixed dose rate (FDR) gemcitabine (C) and capecitabine (G) has been demonstrated to be well tolerated in patients with advanced cancers. To determine the activity and safety of this combination in metastatic metastatic biliary tract cancer patients, a phase II trial was conducted. Methods: Patients with unresectable BTC who had pathologically confirmed adenocarcinoma, no prior chemotherapy, ECOG PS < 2 and measurable disease were enrolled. Treatment consisted of FDR G at 800 mg/m(2) infused in 80 minutes on days 1 and 8 every 21 days with C administered orally bid in equal doses (650 mg/m 2 bid) for 14 days (28 doses). Results: Between Feb 2005 and Sept 2008, 30 pts were enrolled. Median age was 67 (45–86) with 14 males. 30 pts were evaluable for response and toxicity. A total of 219 cycles were administered (median, 8; range, 2–16). One patient achieved CR and 8 pts achieved PR giving an overall response rate of 30.0% in intention-to-treat population (95% CI, 19.2–42.6%). And 11 pts (36.6%) had stable disease. The median time to progression of all patients was 7.4 months (mo) (95% CI, 3.2–19.5). The median overall survival was 15.3 mo (95% CI, 4.6–27.9). Grade 3/4 neutropenia and thrombocytopenia were noted in 13.3% and 6.6% of the pts, respectively. Grade 2/3 non-hematologic toxicities were asthenia (50.0 % of pts), diarrhea (16.6%), stomatitis (23.3%) and hand-foot syndrome (6.6%). There was no treatment-related death. Gemcitabine was skipped at least once/reduced in 20%/15% of the patients, respectively. Capecitabine was skipped at least once/reduced in 20%/25% of the patients, respectively. Conclusions: The combination of FDR gemcitabine and capecitabine in this three week cycle is safe and seems to have advantages in activity over other regimens in advanced biliary cancer. No significant financial relationships to disclose." @default.
- W2596095025 created "2017-03-23" @default.
- W2596095025 creator A5012034272 @default.
- W2596095025 creator A5029788016 @default.
- W2596095025 creator A5035940602 @default.
- W2596095025 creator A5038347927 @default.
- W2596095025 creator A5047814180 @default.
- W2596095025 creator A5050187820 @default.
- W2596095025 creator A5078689516 @default.
- W2596095025 creator A5081470600 @default.
- W2596095025 creator A5082066847 @default.
- W2596095025 creator A5091765229 @default.
- W2596095025 date "2009-05-20" @default.
- W2596095025 modified "2023-10-17" @default.
- W2596095025 title "Fixed dose rate (FDR) gemcitabine (G) and capecitabine (C) in patients with metastatic biliary tract cancer (BTC): Final results of phase II trial" @default.
- W2596095025 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e15510" @default.
- W2596095025 hasPublicationYear "2009" @default.
- W2596095025 type Work @default.
- W2596095025 sameAs 2596095025 @default.
- W2596095025 citedByCount "2" @default.
- W2596095025 countsByYear W25960950252015 @default.
- W2596095025 crossrefType "journal-article" @default.
- W2596095025 hasAuthorship W2596095025A5012034272 @default.
- W2596095025 hasAuthorship W2596095025A5029788016 @default.
- W2596095025 hasAuthorship W2596095025A5035940602 @default.
- W2596095025 hasAuthorship W2596095025A5038347927 @default.
- W2596095025 hasAuthorship W2596095025A5047814180 @default.
- W2596095025 hasAuthorship W2596095025A5050187820 @default.
- W2596095025 hasAuthorship W2596095025A5078689516 @default.
- W2596095025 hasAuthorship W2596095025A5081470600 @default.
- W2596095025 hasAuthorship W2596095025A5082066847 @default.
- W2596095025 hasAuthorship W2596095025A5091765229 @default.
- W2596095025 hasConcept C121608353 @default.
- W2596095025 hasConcept C126322002 @default.
- W2596095025 hasConcept C141071460 @default.
- W2596095025 hasConcept C2776694085 @default.
- W2596095025 hasConcept C2777063308 @default.
- W2596095025 hasConcept C2777909004 @default.
- W2596095025 hasConcept C2780258809 @default.
- W2596095025 hasConcept C2908647359 @default.
- W2596095025 hasConcept C29730261 @default.
- W2596095025 hasConcept C3017919176 @default.
- W2596095025 hasConcept C31760486 @default.
- W2596095025 hasConcept C526805850 @default.
- W2596095025 hasConcept C71924100 @default.
- W2596095025 hasConcept C90924648 @default.
- W2596095025 hasConcept C99454951 @default.
- W2596095025 hasConceptScore W2596095025C121608353 @default.
- W2596095025 hasConceptScore W2596095025C126322002 @default.
- W2596095025 hasConceptScore W2596095025C141071460 @default.
- W2596095025 hasConceptScore W2596095025C2776694085 @default.
- W2596095025 hasConceptScore W2596095025C2777063308 @default.
- W2596095025 hasConceptScore W2596095025C2777909004 @default.
- W2596095025 hasConceptScore W2596095025C2780258809 @default.
- W2596095025 hasConceptScore W2596095025C2908647359 @default.
- W2596095025 hasConceptScore W2596095025C29730261 @default.
- W2596095025 hasConceptScore W2596095025C3017919176 @default.
- W2596095025 hasConceptScore W2596095025C31760486 @default.
- W2596095025 hasConceptScore W2596095025C526805850 @default.
- W2596095025 hasConceptScore W2596095025C71924100 @default.
- W2596095025 hasConceptScore W2596095025C90924648 @default.
- W2596095025 hasConceptScore W2596095025C99454951 @default.
- W2596095025 hasLocation W25960950251 @default.
- W2596095025 hasOpenAccess W2596095025 @default.
- W2596095025 hasPrimaryLocation W25960950251 @default.
- W2596095025 hasRelatedWork W1996538874 @default.
- W2596095025 hasRelatedWork W2039108952 @default.
- W2596095025 hasRelatedWork W2074182195 @default.
- W2596095025 hasRelatedWork W2081083325 @default.
- W2596095025 hasRelatedWork W2277240766 @default.
- W2596095025 hasRelatedWork W2417928583 @default.
- W2596095025 hasRelatedWork W2570746401 @default.
- W2596095025 hasRelatedWork W2596095025 @default.
- W2596095025 hasRelatedWork W2607397704 @default.
- W2596095025 hasRelatedWork W4236867716 @default.
- W2596095025 isParatext "false" @default.
- W2596095025 isRetracted "false" @default.
- W2596095025 magId "2596095025" @default.
- W2596095025 workType "article" @default.